lincomycin hydrochloride

FDA Drug Profile — LINCOMYCIN, Lincocin, Lincomycin, lincomycin hydrochloride, Lincomycin hydrochloride

lincomycin hydrochloride is listed in the FDA National Drug Code directory with 9 NDC codes, marketed under brand names including LINCOMYCIN, Lincocin, Lincomycin. Available dosage forms: powder, injection, solution.

Drug details

Generic Name
lincomycin hydrochloride
Brand Names
LINCOMYCIN, Lincocin, Lincomycin, lincomycin hydrochloride, Lincomycin hydrochloride
Application Number
ANDA201746
Sponsor
Xinyu Pharmaceutical Co.,Ltd
NDC Codes
9
Dosage Forms
POWDER, INJECTION, SOLUTION
Routes
INTRAMUSCULAR, INTRAVENOUS, SUBCONJUNCTIVAL
Active Ingredients
LINCOMYCIN HYDROCHLORIDE

Warnings

WARNINGS See WARNING Box. Clostridium difficile associated diarrhea Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Lincomycin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated. Hypersensitivity Serious hypersensitivity reactions, including anaphylaxis and erythema multiforme, have been reported with use of Lincomycin Injection. If an allergic reaction to Lincomycin occurs, discontinue the drug. (See ADVERSE REACTIONS ) Benzyl Alcohol Toxicity in Pediatric Patients ("Gasping Syndrome") Lincomycin Injection Sterile Solution contains benzyl alcohol as a preservative. The preservative benzyl alcohol has been associated with serious adverse events, including the "gasping syndrome", and death in pediatric patients. Although normal therapeutic doses of this product ordinarily deliver amounts of benzyl alcohol that are substantially lower than those reported in association with the "gasping syndrome", the minimum amount of benzyl alcohol at which toxicity may occur is not known. The risk of benzyl alcohol toxicity depends on the quantity administered and the liver and kidney's capacity to detoxify the chemical. Premature and low-birth weight infants may be more likely to develop toxicity. Use in Meningitis — Although lincomycin appears to diffuse into cerebrospinal fluid, levels of lincomycin in the CSF may be inadequate for the treatment of meningitis.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.